Ex Vivo CAR-T Cell Therapy, How It Works
A 5-step animated schematic: from T cell collection to patient reinfusion
An animated schematic of ex vivo CAR-T cell therapy showing all 5 manufacturing steps: leukapheresis, T cell isolation, viral transduction, ex vivo expansion, and patient reinfusion.
Ex vivo CAR-T cell therapy is the gold standard in adoptive cell therapy. Unlike in vivo approaches, ex vivo manufacturing gives scientists full control over every step of the engineering process outside the patient's body.
The five-step process begins with leukapheresis, a blood draw that filters and collects T cells from the patient. These cells are isolated, and a viral vector (typically lentiviral or retroviral) delivers the chimeric antigen receptor (CAR) gene directly into the T cell DNA.
Once transduced, the cells undergo ex vivo expansion in a bioreactor system, multiplying from millions to billions over 10 to 14 days. The final product is infused back into the patient, where CAR-T cells patrol the body and destroy cancer cells expressing the target antigen.
This animated schematic was built to help biotech teams, clinical educators, and MOA presenters communicate the manufacturing complexity of ex vivo CAR-T therapy in a format that is fast, clear, and scientifically accurate.
A 2025 review published in the Journal of Translational Medicine (26,000+ accesses, 63 citations) highlights the ongoing transition from ex vivo to in vivo approaches, underscoring how central the ex vivo model remains as the current standard of care.
Reference: https://link.springer.com/article/10.1186/s12967-024-06052-3
Need a schematic like this?
Schematics are priced per scope. Tell us about your therapy and we will send a custom quote.
Get custom pricingSchematics start from custom-quote pricing. Standard turnaround: 15-25 days.
